MIM
TPTX

Monashee Investment Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Monashee Investment Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-55,000
Closed -$3.55M – 295
2020
Q2 		$3.55M Buy
+55,000
New +$3.17M 0.53% 59

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Monashee Investment Management's TPTX Position: Q3 2020 in Review

Monashee Investment Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2020, closing a stake of 55,000 shares — an estimated $3.55M sold.

Monashee Investment Management first reported a position in TPTX in Q2 2020 and held it in 1 quarter. The position peaked at $3.55M in Q2 2020. 166 funds tracked by Wall St. Rank hold TPTX as of Q3 2020.

  • Monashee Investment Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Monashee Investment Management sold 55,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $3.55M.
  • Monashee Investment Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Monashee Investment Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.55M in Q2 2020.
  • 166 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Monashee Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.